Latest quarter
Merck reported third-quarter revenue of $18.1 billion, above the $17.2 billion consensus, and adjusted earnings of $2.49 per share, above the $2.12 consensus. Revenue rose from $17.3 billion a year earlier, while diluted earnings per share fell to $2.04 from $2.32.
The filing attributed sales growth to oncology, cardiometabolic and specialty products, and animal health, partly offset by a decline in vaccines and infectious diseases. Combined Keytruda and Keytruda Qlex sales grew 6%, with the filing citing higher U.S. pricing and demand. Gardasil sales benefited from U.S. public-sector purchasing and higher net pricing, while generic competition reduced sales of Januvia and Janumet.
Merck’s gross margin fell to 72.9% from 77.7%; the filing cited higher intangible-asset amortization, restructuring costs, acquisition-related inventory adjustments and production costs. Operating margin fell to 31.9% from 37.9%. In the preceding quarter, Merck generated $4.5 billion in free cash flow, compared with $2.5 billion in Q2 FY2025.
| Q3 FY2026 | Q3 FY2025 | Change | |
|---|---|---|---|
| Revenue | $18.1 billion | $17.3 billion | 4.68% |
| Diluted EPS | $2.04 | $2.32 | −11.9% |
| Gross margin | 72.9% | 77.7% | −4.7 percentage points |
| Operating margin | 31.9% | 37.9% | −6.0 percentage points |
| Free cash flow | $4.5 billion | $2.5 billion | 77.0% |
| Against the consensus | Reported | Consensus | Result |
|---|---|---|---|
| Adjusted EPS | $2.49 | $2.12 | Beat by 17.5% |
| Revenue | $18.1 billion | $17.2 billion | Beat by 4.94% |
Adjusted EPS is the figure the consensus estimates, not the GAAP EPS above.
What management said on the call
CFO Caroline Litchfield said Keytruda family growth reflected uptake in earlier-stage cancers and continued demand in metastatic disease. Keytruda Qlex, the injectable version, had $830 million in quarterly sales. Asked about adoption, oncology president Yanni Oosthuizen reiterated the objective of 30% to 40% U.S. adoption by the end of 2027. He said Merck would not supply the product in several European countries while it works to overturn a Dutch court decision.
Litchfield said favorable U.S. purchase timing contributed approximately $550 million to third-quarter sales. In response to a question, she said the Keytruda and Winrevair portions should unwind in the fourth quarter; most of the vaccine benefit, predominantly Gardasil, should unwind in 2027.
On LipFendra, specialty business president Brian Ford said the quarter brought more than 11,000 prescriptions from over 6,500 prescribers. He said sampling and coupon programs would affect near-term revenue while Merck negotiates access with payers. CEO Rob Davis said the company was not giving specifics on its revenue forecasts for the product at that moment.
Litchfield said quarterly non-GAAP gross margin decreased to 81.4%, while operating expenses rose as Merck invested in launches and its pipeline. Asked about 2027, she described it as another investment year and said new products and animal health would be partly offset by more than $2 billion in headwinds from generic competition and losses of exclusivity. She also expected Keytruda growth to moderate as several indications reach peak penetration, with pricing pressure outside the U.S. and policy dynamics in Germany under review.
Davis said clinical data had increased his confidence in Merck’s longer-term revenue opportunity and that the company expected to raise its earlier $70 billion figure.
Guidance
Merck narrowed its FY2026 revenue outlook to $66.8 billion–$67.3 billion from $66.3 billion–$67.3 billion. It raised its non-GAAP EPS range to $2.77–$2.82 from $2.66–$2.76.
Merck now expects non-GAAP operating expenses of $42.4 billion–$42.9 billion, compared with $42.0 billion–$42.7 billion previously. Its expected non-GAAP tax rate is 32% to 33%, down from 35% to 36%.
| Metric | For | Guide | Previous guide | Change |
|---|---|---|---|---|
| Market share, Keytruda Qlex US | FY2027 | 30.0%–40.0% | — | New |
| Operating expenses, Underlying | FY2027 | Merck expects underlying operating expenses to increase at a mid to high single-digit rate in FY2027. | — | — |
| Gross margin | FY2027 | Merck expects its gross margin to increase in FY2027. | — | — |
| Revenue, Keytruda | FY2027 | Merck expects Keytruda revenue growth to moderate in FY2027. | — | — |
| Revenue | FY2027 | Merck expects modest revenue growth in FY2027. | — | — |
| Share repurchases | FY2026 | $3.0 billion | — | New |
| EPS, non-GAAP | FY2026 | $2.77–$2.82 | — | New |
| Tax rate, non-GAAP | FY2026 | 32.0%–33.0% | 35.0%–36.0% | Cut |
| Operating expenses, non-GAAP | FY2026 | $42.4 billion–$42.9 billion | — | New |
| Gross margin, non-GAAP | FY2026 | 81.0% | — | New |
| Revenue | FY2026 | $66.8 billion–$67.3 billion | $66.3 billion–$67.3 billion | Held |
| EPS, non-GAAP | FY2026 | $2.66–$2.76 | — | — |
| Operating expenses, Other Expense | FY2026 | $1.4 billion | — | New |
| Tax rate | FY2026 | 35.0%–36.0% | — | New |
| Gross margin | FY2026 | 81.0% | — | New |
| EPS | FY2026 | $2.66–$2.76 | — | New |